I farmaci emostatici

Translated title of the contribution: Hemostatic drugs

Research output: Contribution to journalArticle

Abstract

Specific treatment of bleeding is frequently not feasible, because in many clinical situations bleeding is the result of multiple and complex defects of hemostasis, or because no cause can be identified. In these situations, non-transfusional agents that potentiate hemostasis may help to stop bleeding. Hemostatic agents may also be needed to meet religious requests to avoid blood transfusion (i.e., by Jehovah's witnesses). Finally, they may be needed prophylactically, when surgical operations are routinely accompanied by large blood losses that require multiple transfusions that carry a risk of transmitting bloodborne infections agents. Interest in the pharmacological reduction of bleeding rapidly increased in the 1980's, when it was recognized that the acquired immunodeficiency syndrome could result from transfusion of blood contaminated with the human immunodeficiency virus. A number of pharmacological agents have been claimed to have hemostatic properties, but only a few of them are of proven clinical value. This article reviews the clinical indications of synthetic antifibrinolytic amino acids (epsilon-aminocaproic acid and tranexamic acid), aprotinin, desmopressin and conjugated estrogens.

Original languageItalian
Pages (from-to)144-152
Number of pages9
JournalAnnali Italiani di Medicina Interna
Volume12
Issue number3
Publication statusPublished - 1997

Fingerprint

Hemostatics
Hemorrhage
Hemostasis
Blood Transfusion
Pharmaceutical Preparations
Jehovah's Witnesses
Pharmacology
Tranexamic Acid
Aminocaproic Acid
Conjugated (USP) Estrogens
Deamino Arginine Vasopressin
Antifibrinolytic Agents
Aprotinin
Acquired Immunodeficiency Syndrome
HIV
Amino Acids
Infection
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

I farmaci emostatici. / Mannucci, P. M.

In: Annali Italiani di Medicina Interna, Vol. 12, No. 3, 1997, p. 144-152.

Research output: Contribution to journalArticle

@article{cd86c0e9ec3c475ebdf4de9c150a6748,
title = "I farmaci emostatici",
abstract = "Specific treatment of bleeding is frequently not feasible, because in many clinical situations bleeding is the result of multiple and complex defects of hemostasis, or because no cause can be identified. In these situations, non-transfusional agents that potentiate hemostasis may help to stop bleeding. Hemostatic agents may also be needed to meet religious requests to avoid blood transfusion (i.e., by Jehovah's witnesses). Finally, they may be needed prophylactically, when surgical operations are routinely accompanied by large blood losses that require multiple transfusions that carry a risk of transmitting bloodborne infections agents. Interest in the pharmacological reduction of bleeding rapidly increased in the 1980's, when it was recognized that the acquired immunodeficiency syndrome could result from transfusion of blood contaminated with the human immunodeficiency virus. A number of pharmacological agents have been claimed to have hemostatic properties, but only a few of them are of proven clinical value. This article reviews the clinical indications of synthetic antifibrinolytic amino acids (epsilon-aminocaproic acid and tranexamic acid), aprotinin, desmopressin and conjugated estrogens.",
author = "Mannucci, {P. M.}",
year = "1997",
language = "Italian",
volume = "12",
pages = "144--152",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "3",

}

TY - JOUR

T1 - I farmaci emostatici

AU - Mannucci, P. M.

PY - 1997

Y1 - 1997

N2 - Specific treatment of bleeding is frequently not feasible, because in many clinical situations bleeding is the result of multiple and complex defects of hemostasis, or because no cause can be identified. In these situations, non-transfusional agents that potentiate hemostasis may help to stop bleeding. Hemostatic agents may also be needed to meet religious requests to avoid blood transfusion (i.e., by Jehovah's witnesses). Finally, they may be needed prophylactically, when surgical operations are routinely accompanied by large blood losses that require multiple transfusions that carry a risk of transmitting bloodborne infections agents. Interest in the pharmacological reduction of bleeding rapidly increased in the 1980's, when it was recognized that the acquired immunodeficiency syndrome could result from transfusion of blood contaminated with the human immunodeficiency virus. A number of pharmacological agents have been claimed to have hemostatic properties, but only a few of them are of proven clinical value. This article reviews the clinical indications of synthetic antifibrinolytic amino acids (epsilon-aminocaproic acid and tranexamic acid), aprotinin, desmopressin and conjugated estrogens.

AB - Specific treatment of bleeding is frequently not feasible, because in many clinical situations bleeding is the result of multiple and complex defects of hemostasis, or because no cause can be identified. In these situations, non-transfusional agents that potentiate hemostasis may help to stop bleeding. Hemostatic agents may also be needed to meet religious requests to avoid blood transfusion (i.e., by Jehovah's witnesses). Finally, they may be needed prophylactically, when surgical operations are routinely accompanied by large blood losses that require multiple transfusions that carry a risk of transmitting bloodborne infections agents. Interest in the pharmacological reduction of bleeding rapidly increased in the 1980's, when it was recognized that the acquired immunodeficiency syndrome could result from transfusion of blood contaminated with the human immunodeficiency virus. A number of pharmacological agents have been claimed to have hemostatic properties, but only a few of them are of proven clinical value. This article reviews the clinical indications of synthetic antifibrinolytic amino acids (epsilon-aminocaproic acid and tranexamic acid), aprotinin, desmopressin and conjugated estrogens.

UR - http://www.scopus.com/inward/record.url?scp=0030834986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030834986&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0030834986

VL - 12

SP - 144

EP - 152

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 3

ER -